Increased SPARC expression in primary angle closure glaucoma iris

Molecular Vision

Volumn 14, Issue , 2008, Pages 1886-1892

  Chua, Jocelyn ^a   Seet, Li Fong ^b   Jiang, Yu Zhen ^b   Su, Roseline ^b   Htoon, Hla Myint ^b   Charlton, Amanda ^c   Aung, Tin ^a,b,c   Wong, Tina T ^a,b  

^a SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^b SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; OSTEONECTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN TISSUE; IRIDECTOMY; IRIS; IRIS BLOOD VESSEL; KERATOPLASTY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; SINGAPORE; TRABECULECTOMY;

AGED; COLLAGEN TYPE I; DEMOGRAPHY; FEMALE; GENE EXPRESSION REGULATION; GLAUCOMA, ANGLE-CLOSURE; HUMANS; IRIS; MALE; OSTEONECTIN; PREOPERATIVE CARE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS;

EID: 55349140088     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Quigley HA, Congdon NG, Friedman DG. Glaucoma in China (and worldwide): changes in established thinking will decrease preventable blindness. Br J Ophthalmol 2001; 85:1271-2.
2. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol 2001; 85:1277-82.
3. Huang EC, Barocas VH. Active iris mechanics and pupillary block: steady-state analysis and comparison with anatomical risk factors. Ann Biomed Eng 2004; 32:1276-85.
4. Ningli W, Wenbin Z, Tiancai Y, Qiang Y, Mingying L, Meihua L. Studies of primary angle closure glaucoma in China. Yan Ke Xue Bao. 1997; 13:120-4.
5. Konstas AG, Marchall GE, Lee WR. Immunocytochemical localisation of collagens (1-V) in the human iris. Graefes Arch Clin Exp Ophthalmol 1990; 228:180-6.
6. Rittig M, Lutjen-Drecoll E, Rauterberg J, Jander R, Mollenhauer J. Type-VI collagen in the human iris and ciliary body. Cell Tissue Res 1990; 259:305-12.
7. He M, Lu Y, Liu X, Ye T, Foster PJ. Histologic changes of the iris in the development of angle closure in Chinese eyes. J Glaucoma 2008; 17:386-92.
8. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2001; 19:816-27.
9. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J Biol Chem 2007; 282:22062-71.
10. Taneda S, Pippin JW, Sage EH, Hudkins KL, Takeuchi Y, Couser WG, Alpers CE. Amelioration of diabetic nephropathy in SPARC-null mice. J Am Soc Nephrol 2003; 14:968-80.
11. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH, Zern MA. Expression of SPARC in normal and fibrotic livers. Hepatology 1995; 21:847-54.
12. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin and thrombospondin in pulmonary fibrosis. Am J Pathol 1995; 147:1759-69.
13. Pichler RH, Hugo C, Shankland SJ, Reed MJ, Bassuk JA, Andoh TF, Lombardi DM, Schwartz SM, Bennett WM, Alpers CE, Sage EH, Johnson RJ, Couser WG. SPARC is expressed in renal interstitial fibrosis and in renal vascular injury. Kidney Int 1996; 50:1978-89.
14. Vuorio T, Kahari VM, Black C, Vuorio EJ. Expression of osteonectin, decorin and transforming growth factor-beta-1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. J Rheumatol 1991; 18:247-51.
15. Basu A, Kligman LH, Samulewicz SJ, Howe CC. Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40). BMC Cell Biol 2001; 2:15.
16. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049-54.
17. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, Sage EH. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 2003; 120:949-55.
18. Kim SY, Ondhia N, Vidgen D, Malaval L, Ringuette M, Kalnins VI. Spatiotemporal distribution of SPARC/osteonectin in developing and mature chicken retina. Exp Eye Res 1997; 65:681-9.
19. Martinek N, Shahab J, Sodek J, Ringuette M. Is SPARC an evolutionarily conserved collagen chaperone? J Dent Res 2007; 86:296-305.
20. Martinek N, Zou R, Berg M, Sodek J, Ringuette M. Evolutionaary conservation and association of SPARC with the basal lamina in Drosophila. Dev Genes Evol 2002; 212:124-33.
21. Rodríguez R, Moreira EF, Bok D, Kantorow M. Osteonectin/SPARC secreted by RPE and localized to the outer plexiform layer of the monkey retina. Invest Ophthalmol Vis Sci 2000; 41:2438-44.
22. Rhee DJ, Fariss RN, Brekken R, Sage EH, Russell P. The matricellular protein SPARC is expressed in human trabecular meshwork. Exp Eye Res 2003; 77:601-7.
23. Norose K, Clark JI, Syed NA, Basu A, Heber-Katz E, Sgae EH, Howe CC. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998; 39:2674-80.
24. Gotoh N, Perdue NR, Matsushima H, Sage EH, Yan Q, Clark JI. An in vitro model of posterior capsular opacity:SPARC and TGF-β2 minimises epithelial-to-mesenchymal transition in lens epithelium. Invest Ophthatmol Vis Sci 2007; 48:4679-87.
25. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14:608-16.
26. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994; 112:1431-45.
27. Ozdal PC, Deschênes J, Rudzinski M, Antecka E, Baines MG. Chemotactic and chemokinetic properties of topical ophthalmic preparations. Curr Eye Res 2002; 25:363-8.
28. Pisella PJ, Debbasch C, Hamard P, Creuzot-Garcher C, Rat P, Brignole F, Baudouin C. Conjunctival proinflammatory and proapoptotic effects of latanopfost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci 2004; 45:1360-8.
29. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthahnol Vis Sci 2005; 46:2444-50.
30. Arcieri ES, Santana A, Rocha FN, Guapo GL, Costa VP. Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: a 6-month randomized trial. Arch Ophthalmol 2005; 123:186-92.
31. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77:668-72.
32. Fechtner RD, Khouri AS, Zimmerman TJ, Bullock J, Feldman R, Kulkarni P, Michael AJ, Realini T, Warwar R. Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998; 126:37-41.